| DIRECT COMPETITOR COMPARISON | |
| SIGA | CLDX | EBS | SNY | Industry | | Market Cap: | 331.46M | 145.05M | 437.02M | 103.03B | 165.99M | | Employees: | 43 | 78 | 587 | 98,213 | 95 | | Qtrly Rev Growth (yoy): | 110.60% | 70.90% | -23.50% | 8.50% | 20.50% | | Revenue (ttm): | 12.35M | 13.44M | 216.73M | N/A | 46.74M | | Gross Margin (ttm): | -30.95% | 100.00% | 48.84% | 75.20% | 68.58% | | EBITDA (ttm): | -10.23M | -28.69M | 45.09M | N/A | -6.21M | | Oper Margins (ttm): | -86.65% | -233.99% | 18.45% | N/A | 2.25% | | Net Income (ttm): | -20.24M | -31.04M | 28.36M | N/A | N/A | | EPS (ttm): | -0.556 | -1.961 | 0.905 | N/A | -0.17 | | P/E (ttm): | N/A | N/A | 15.68 | N/A | 18.31 | | PEG (5 yr expected): | N/A | N/A | N/A | 2.54 | 1.01 | | P/S (ttm): | 26.07 | 11.10 | 2.03 | N/A | 4.36 |
|
| CLDX = Celldex Therapeutics, Inc. | | EBS = Emergent BioSolutions, Inc. | | SNY = Sanofi-Aventis | | Industry = Drug Manufacturers - Other | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.08 | 0.49% | 57.77B | 12.45 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.45 | 0.15% | 13.72B | 15.88 | | Genzyme Corp. | GENZ | 51.52 | 2.26% | 13.67B | 29.37 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.98 | 0.04% | 42.28B | 18.17 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.89 | 1.41% | 9.08B | 1038.57 | | Teva Pharmaceutical Industries Limited | TEVA | 53.16 | -0.21% | 46.83B | 48.64 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.81 | 2.05% | 4.01B | 19.49 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 12.08 | 0.00% | 3.00B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.29 | -0.05% | 5.59B | 112.21 | | Pfizer Inc. | PFE | 18.59 | 1.53% | 150.01B | 15.44 | | Johnson & Johnson | JNJ | 63.30 | 0.19% | 174.65B | 13.82 | | GlaxoSmithKline plc | GSK | 42.88 | 1.42% | 108.70B | 13.53 | | Sanofi-Aventis | SNY | 39.46 | 2.15% | 103.03B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.85 | 0.99% | 126.85B | 16.72 | | RHHBY.PK | 42.29 | 2.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 2.50% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.41 | 0.31% | 84.16B | 14.74 | | Bristol-Myers Squibb Co. | BMY | 25.65 | 1.95% | 50.81B | 13.27 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | SNY | | Former chairman in Ratiopharm bid
Wed 2:50pm -
at FT.com | | • | SNY | | A Schizophrenic Move by Merck?
Wed 12:28pm -
at Motley Fool | | • | SNY | | Sanofi Expands Regeneron Agreement
Wed 10:10am -
Zacks.com | | • | SNY | | Worse Than The NBC-Comcast Deal? No Deal
Wed 9:58am -
at Forbes.com | | • | SNY | | Making Flu Vaccine: Eggs Aren't the Only Problem
Wed 8:43am -
at The Wall Street Journal Online | | • | SNY | | Cramer's 'Mad Money' Follow-Up: Nov. 24
Tue, Nov 24 -
at TheStreet.com | | • | SNY | | How Big Pharma Profits from Swine Flu
Tue, Nov 24 -
at BusinessWeek | | • | EBS | | Corporate Profile Emergent BioSolutions Inc.
Mon, Nov 23 -
WILink | | • | EBS | | Md. gov announces biopharmaceutical firm's growth
Thu, Nov 19 -
AP | | • | EBS | | Emergent BioSolutions Enhances Manufacturing Infrastructure with Strategic Acquisition in Baltimore
Fri, Nov 13 -
Business Wire | | • | EBS | | EMERGENT BIOSOLUTIONS INC. Financials
Wed, Nov 11 -
EDGAR Online Financials | | • | CLDX | | CELLDEX THERAPEUTICS, INC. Financials
Wed, Nov 11 -
EDGAR Online Financials | | • | EBS | | New Star Analyst Rankings for EMERGENT BIOSOLUTION
Sun, Nov 8 -
StarMine | | • | CLDX | | CELLDEX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Fri, Nov 6 -
EDGAR Online | | • | CLDX | | Celldex Therapeutics to Present at Merriman Curhan Ford's Investor Summit 2009
Thu, Nov 5 -
Business Wire | | • | CLDX | | New Star Analyst Rankings for Celldex Therapeutics, Inc
Thu, Nov 5 -
StarMine | | • | CLDX | | CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
Wed, Nov 4 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
0.29% Nasdaq 
Competitors
